News & Updates
Filter by Specialty:
Empagliflozin beneficial and well tolerated in acute heart failure
06 Dec 2021
byChristina Lau
Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.